摘要
目的探讨洛铂联合多西他赛在Ⅱb~Ⅲb期高危型人乳头状瘤病毒(high-risk human papilloma virus,HR-HPV)阳性宫颈癌患者中的应用效果。方法选取本院2014年4月至2016年11月收治的Ⅱb~Ⅲb期HR-HPV阳性宫颈癌患者136例,依据随机数字表法分为对照组和观察组,各68例。对照组采用顺铂联合多西他赛治疗,观察组采用洛铂联合多西他赛治疗。比较两组疾病控制率、随访3年生存周期,治疗前、治疗4个疗程后血清细胞因子(bFGF、CD105、VEGF)水平、肿瘤标志物(CA125、SCCA、CEA)水平,不良反应发生率。结果两组疾病控制率比较,差异有统计学意义(P<0.05);观察组生存周期长于对照组(P<0.05);治疗4个疗程后,观察组血清bFGF、CD105、VEGF、CA125、SCCA、CEA水平低于对照组(均P<0.05);两组骨髓抑制、胃肠道反应、肾毒性等不良反应发生率比较,差异无统计学意义(均P>0.05)。结论洛铂联合多西他赛治疗Ⅱb~Ⅲb期HR-HPV阳性宫颈癌患者,疾病控制率高,可降低血清细胞因子与肿瘤标志物水平,延长生存周期,且安全性高。
Objective To explore the application effect of loboplatin combined with docetaxel for patients with stageⅡb-Ⅲb high-risk human papilloma virus(HR-HPV)positive cervical cancer.Methods A total of 136 patients with HR-HPV positive cervical cancer from stageⅡb toⅢb treated at our hospital from April,2014 to November,2016 were selected,and were divided into a control group and an observation group according to the random number table method,with 68 cases in each group.The control group was treated with cisplatin and docetaxel,and the observation group with loboplatin and docetaxel.The disease control rate,three-year survival time during follow-up,serum levels of bFGF,CD105,VEGF,CA125,SCCA,and CEA,and incidence of adverse reactions were compared between the two groups.Results There was a statistical difference in the disease control rate between the two groups(P<0.05).The observation group had a longer life cycle than the control group(P<0.05).After 4 treatment courses,the serum levels of bFGF,CD105,VEGF,CA125,SCCA,and CEA in the observation group were lower than those in the control group(all P<0.05).There were no statistical differences in the incidences of adverse reactions,such as bone marrow suppression,gastrointestinal reaction,and renal toxicity,between the two groups(all P>0.05).Conclusion Loboplatin combined with docetaxel in treatment of patients with stageⅡ-Ⅲb HR-HPV positive cervical cancer has a high disease control rate and high safety,and can reduce serum cytokines and tumor marker levels and prolong their life cycles.
作者
姜媛媛
修瑜晨
于鹏华
赵成琳
Jiang Yuanyuan;Xiu Yuchen;Yu Penghua;Zhao Chenglin(Department of Obstetrics,Haiyang People's Hospital,Haiyang 265100,China)
出处
《国际医药卫生导报》
2020年第20期3115-3117,共3页
International Medicine and Health Guidance News
